Jupiter Neurosciences (JUNS) Research & Development (2023 - 2025)
Jupiter Neurosciences (JUNS) posted quarterly Research & Development of $43684.0 for Q4 2025, down 78.27% year-over-year from $201005.0 in Q4 2024, and down 94.65% quarter-over-quarter from $816697.0 in Q3 2025.
Jupiter Neurosciences (JUNS) Research & Development (2023 - 2025) Analysis & Trends
Jupiter Neurosciences (JUNS) has reported Research & Development for 3 consecutive years, with $43684.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Research & Development fell 78.27% year-over-year to $43684.0; the TTM figure through Dec 2025 stood at $2.1 million (up 323.53% YoY), while the FY2025 annual figure was $2.1 million, up 323.53% from the prior year.
- Research & Development fell to $43684.0 in Q4 2025 per JUNS's latest filing, from $816697.0 in the prior quarter.
- Across five years, Research & Development topped out at $816697.0 in Q3 2025 and bottomed at $43684.0 in Q4 2025.
- Historically, Research & Development has averaged $306342.2 across 3 years, with a median of $220231.5 in 2023.
- On a YoY basis, Research & Development climbed as much as 788.57% in 2025 and fell as far as 78.27% in 2025.
- Jupiter Neurosciences' Research & Development stood at $244730.0 in 2023, then declined by 17.87% to $201005.0 in 2024, then tumbled by 78.27% to $43684.0 in 2025.
- Business Quant data shows JUNS's Research & Development at $43684.0 in Q4 2025, $816697.0 in Q3 2025, and $759448.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.81 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.52 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.30 Bn | 60.11 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.77 Bn | 28.46 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.32 Bn | - | 97.90 Mn |
| 10 | Jupiter Neurosciences | 4.81 Mn | 3.29 Mn | 21,064.00 | 600,353.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 43,684.00 |
| Sep 30, 2025 | 816,697.00 |
| Jun 30, 2025 | 759,448.00 |
| Mar 31, 2025 | 466,745.00 |
| Dec 31, 2024 | 201,005.00 |
| Sep 30, 2024 | 91,911.00 |
| Jun 30, 2024 | 101,077.00 |
| Mar 31, 2024 | 98,667.00 |
| Dec 31, 2023 | 244,730.00 |
| Sep 30, 2023 | 239,458.00 |